AIM: To evaluate fecal calprotectin concentrations (FCCs) in subjects with chronic gastritis and the correlation between FCCs and gastritis activity score. METHODS: FCCs were measured in 61 patients with histological diagnosis of gastritis and in 74 healthy volunteers. Histological grading of gastritis was performed according to the updated Sydney gastritis classification. Patients were subdivided into 2 groups according to the presence/absence of an active gastritis. Patients with chronic active gastritis were divided into 3 subgroups on the basis of the activity score (mild, moderate, marked). FFCs in relation to Helicobacter pylori (H. pylori) infection and proton pump inhibitor (PPI) use were also evaluated. RESULTS: FCCs in patients with chronic active gastritis were not significantly different to FCCs either in subjects with non active gastritis or in healthy controls. Among patients with chronic active gastritis (even marked), FCCs did not significantly differ according to activity score. No significant differences in FCCs were found when considering H. pylori, as well as when considering PPI chronic use. CONCLUSION: FCCs were not significantly increased in subjects with chronic gastritis, even in those patients with a marked neutrophil infiltration.
AIM: To evaluate fecal calprotectin concentrations (FCCs) in subjects with chronic gastritis and the correlation between FCCs and gastritis activity score. METHODS: FCCs were measured in 61 patients with histological diagnosis of gastritis and in 74 healthy volunteers. Histological grading of gastritis was performed according to the updated Sydney gastritis classification. Patients were subdivided into 2 groups according to the presence/absence of an active gastritis. Patients with chronic active gastritis were divided into 3 subgroups on the basis of the activity score (mild, moderate, marked). FFCs in relation to Helicobacter pylori (H. pylori) infection and proton pump inhibitor (PPI) use were also evaluated. RESULTS: FCCs in patients with chronic active gastritis were not significantly different to FCCs either in subjects with non active gastritis or in healthy controls. Among patients with chronic active gastritis (even marked), FCCs did not significantly differ according to activity score. No significant differences in FCCs were found when considering H. pylori, as well as when considering PPI chronic use. CONCLUSION: FCCs were not significantly increased in subjects with chronic gastritis, even in those patients with a marked neutrophil infiltration.
Authors: Javier P Gisbert; Fernando Bermejo; Jose-Lázaro Pérez-Calle; Carlos Taxonera; Isabel Vera; Adrian G McNicholl; Alicia Algaba; Pilar López; Natalia López-Palacios; Marta Calvo; Yago González-Lama; Jose-Antonio Carneros; Marta Velasco; José Maté Journal: Inflamm Bowel Dis Date: 2009-08 Impact factor: 5.325
Authors: T Sipponen; P Kärkkäinen; E Savilahti; K-L Kolho; H Nuutinen; U Turunen; M Färkkilä Journal: Aliment Pharmacol Ther Date: 2008-08-26 Impact factor: 8.171
Authors: Fryderyk Lorenz; Stefan Marklund; Mårten Werner; Richard Palmqvist; Björn Engelbrekt Wahlin; Anders Wahlin Journal: Sci Rep Date: 2015-01-21 Impact factor: 4.379
Authors: Thomas C C Boerlage; Floris Westerink; Dennis C W Poland; Inge L Huibregtse; Yair I Z Acherman; Victor E A Gerdes Journal: Obes Surg Date: 2016-12 Impact factor: 4.129